New Drugs and Regulation · us
FDA Approves First Dual BAFF/APRIL Inhibitor, Adding a New Treatment Pathway for IgA Nephropathy
By simultaneously suppressing two B-cell survival signals, atacicept targets IgA nephropathy and has been approved to reduce proteinuria in high-risk adult patients; the approval also shifts the competitive focus further upstream toward the disease’s immune mechanisms.
Treatment options for IgA nephropathy have expanded rapidly in recent years, and a biologic with a different mechanism of action has now joined them. The U.S. Food and Drug Administration (FDA) has approved Vera Therapeutics’ atacicept, marketed as Trutakna, to reduce proteinuria in adults with primary IgA nephropathy who are at risk of disease progression. It is also the first FDA-approved drug to inhibit both BAFF and APRIL.
IgA nephropathy arises when the immune system produces abnormal IgA antibodies and related immune complexes, which are deposited in the kidney’s glomeruli and gradually cause inflammation and tissue damage. Proteinuria reflects damage to the kidney’s filtration barrier and is an important indicator for assessing the risk of disease progression and response to treatment; some patients may eventually progress to kidney failure.
Atacicept targets the pathway involved in B cells and antibody production. BAFF and APRIL are both signaling molecules that support the survival and maturation of B cells, particularly antibody-secreting cells. Blocking both is intended to reduce the source of abnormal immunoglobulins that contribute to immune-mediated kidney injury. This distinguishes it from treatment strategies that primarily control blood pressure or intraglomerular pressure, or suppress inflammation more broadly.
The significance of this approval lies not only in the addition of another drug, but also in showing that IgA nephropathy drug development is extending beyond kidney function protection to upstream immune pathology. For patients, different mechanisms may create more scope to tailor treatment according to disease course and risk stratification; for drug developers, future competition will depend on whether improvements in proteinuria translate into durable protection of kidney function and whether the drug can be safely combined with existing therapies.
However, the currently available source summaries do not specify the trial size underlying the FDA approval, the magnitude of proteinuria reduction, follow-up duration, eligibility conditions, or safety results, and therefore do not allow the relative efficacy of atacicept and other IgA nephropathy drugs to be compared. Inhibiting B-cell survival signals may also affect immunoglobulins and defenses against infection, and the actual risks must still be assessed using the full prescribing information, clinical trial data, and postmarketing surveillance.
The approval therefore establishes a clinical role for dual BAFF/APRIL inhibition in IgA nephropathy, but it is not the endpoint for efficacy comparisons. The long-term rate of kidney function decline, infection-related and immune-related safety, and the sequencing of different treatments will determine whether Trutakna can progress from an option for reducing proteinuria to an important therapy that alters the course of the disease.